Direkt zum Inhalt
Merck
  • Cardiorespiratory, gastrointestinal, and analgesic effects of morphine sulfate in conscious healthy horses.

Cardiorespiratory, gastrointestinal, and analgesic effects of morphine sulfate in conscious healthy horses.

American journal of veterinary research (2012-05-25)
Juliana P Figueiredo, William W Muir, Richard Sams
ZUSAMMENFASSUNG

To compare the cardiorespiratory, gastrointestinal, analgesic, and behavioral effects between IV and IM administration of morphine in conscious horses with no signs of pain. 6 healthy adult horses. Horses received saline (0.9% NaCl) solution (IM or IV) or morphine sulfate (0.05 and 0.1 mg/kg, IM or IV) in a randomized, masked crossover study design. The following variables were measured before and for 360 minutes after drug administration: heart and respiratory rates; systolic, diastolic, and mean arterial blood pressures; rectal temperature; arterial pH and blood gas variables; intestinal motility; and response to thermal and electrical noxious stimuli. Adverse effects and horse behavior were also recorded. Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide were measured via liquid chromatography-mass spectrometry. No significant differences in any variable were evident after saline solution administration. Intravenous and IM administration of morphine resulted in minimal and short-term cardiorespiratory, intestinal motility, and behavioral changes. A decrease in gastrointestinal motility was detected 1 to 2 hours after IM administration of morphine at doses of 0.05 and 0.1 mg/kg and after IV administration of morphine at a dose of 0.1 mg/kg. Morphine administration yielded no change in any horse's response to noxious stimuli. Both morphine-3-glucuronide and morphine-6-glucuronide were detected in plasma after IV and IM administration of morphine. Clinically relevant doses of morphine sulfate yielded minimal and short-term behavioral and intestinal motility effects in healthy horses with no signs of pain. Neither dose of morphine affected their response to a noxious stimulus.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Morphine-3-β-D-glucuronide solution, 1 mg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine-6-β-D-glucuronide solution, 1.0 mg/mL in methanol: water (2:8), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine-3-β-D-glucuronide solution, 100 μg/mL in methanol: water ( 50:50(v/v)), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine-6-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®